Summit partners with AstraZeneca and Daiichi on cancer drug trial

· Health · United States · United Kingdom

Summit Therapeutics has agreed to a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to test its Trop-2-directed antibody-drug conjugate with Datroway. The news came alongside other pipeline updates in the industry.

Why it matters：Combination trials pairing antibody-drug conjugates with other targeted therapies are becoming a standard route to expand labeling and market reach, and this tie-up tests whether Summit's asset can compete in a crowded field.

Key points

  • Summit will test its Trop-2-directed antibody-drug conjugate with Datroway.
  • The partners are AstraZeneca and Daiichi Sankyo.
  • The deal is a clinical trial collaboration, not a full licensing agreement.

Sources (original reporting)

More stories from this day